<DOC>
	<DOCNO>NCT00943111</DOCNO>
	<brief_summary>This Phase 3 study design confirm efficacy safety eliglustat tartrate ( Genz-112638 ) participants Gaucher disease type 1 reach therapeutic goal enzyme replacement therapy ( ERT ) .</brief_summary>
	<brief_title>A Study Eliglustat Tartrate ( Genz-112638 ) Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy ( ENCORE )</brief_title>
	<detailed_description>Gaucher disease characterize lysosomal accumulation glucosylceramide due impair glucosylceramide hydrolysis . Gaucher disease type 1 , common form , account great ( &gt; ) 90 % case involve central nervous system ( CNS ) . Typical manifestation Gaucher disease type 1 include splenomegaly , hepatomegaly , thrombocytopenia , anemia , bone disease , decrease quality life . The disease manifestation cause accumulation glucosylceramide ( storage material ) macrophage ( call Gaucher cell ) infiltrate spleen liver well tissue . Eliglustat tartrate small molecule drug develop oral therapy act specifically inhibit production storage material Gaucher cell . This study design determine efficacy , safety , PK eliglustat tartrate adult participant Gaucher disease type 1 stabilize ERT .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<mesh_term>Eliglustat</mesh_term>
	<criteria>The participant ( and/or parent/legal guardian ) willing able provide sign informed consent prior studyrelated procedure perform The participant least 18 year old time randomization The participant confirm diagnosis Gaucher disease type 1 The participant receive treatment ERT least 3 year . Within 9 month prior randomization , participant receive total monthly dose 30 130 Units/kilogram least 6 month The participant reach Gaucher disease therapeutic goal prior randomization Female participant childbearing potential must document negative pregnancy test prior dose . In addition , female participant childbearing potential must use medically accepted form contraception throughout study The participant partial total splenectomy within 3 year prior randomization The participant receive substrate reduction therapy Gaucher disease within 6 month prior randomization The participant Gaucher disease type 2 3 suspect Gaucher disease type 3 The participant clinically significant disease , Gaucher disease , include cardiovascular , renal , hepatic , gastrointestinal ( GI ) , pulmonary , neurologic , endocrine , metabolic ( e.g . hypokalemia , hypomagnesemia ) , psychiatric disease , medical condition , serious intercurrent illness may confound study result , opinion Investigator , may preclude participation study The participant test positive human immunodeficiency virus ( HIV ) antibody , Hepatitis C antibody , Hepatitis B surface antigen The participant receive investigational product within 30 day prior randomization The participant pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Gaucher disease ,</keyword>
	<keyword>Genz-112638 ,</keyword>
	<keyword>beta-glucosidase ,</keyword>
	<keyword>acid ÃŸ-glucosidase ,</keyword>
	<keyword>glucocerebrosidase ,</keyword>
	<keyword>glucosylceramide ,</keyword>
	<keyword>D-glucosyl-N-acylsphingosine glucohydrolase ,</keyword>
	<keyword>substrate reduction therapy</keyword>
</DOC>